A Phase 1/2 interventional study of MyoScience Tissue Remodeling Device in Facial Rhytides, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to female participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-24.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 1/2, Interventional, and Treatment
A prospective, non-randomized study to evaluate the performance of the MyoScience Tissue Remodeling Device for the treatment of glabellar lines (frown lines), lateral orbital lines (crow's feet), and frontalis lines (horizontal forehead lines).
217 studies on the registry are indexed under Facies; 35 are open to participants now.
This study's enrollment of 380 is above the median of 40 across 161 interventional studies indexed under Facies.
Browse Facies studies →Pacira Pharmaceuticals, Inc is the lead sponsor of 100 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: MyoScience Tissue Remodeling Device
Percutaneous treatment with the MyoScience device
Investigators' and subjects'rating of line severity in the target areas at rest and in animation at each follow-up interval.
Time frame: Up to 6 months
Incidence of adverse events
Time frame: Up to 6 months
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pacira Pharmaceuticals, Inc